The AusBiotech Health Technology Assessment (HTA) Workshop “Reimbursed & Ready: Winning in the Australian MedTech Market” will provide a comprehensive overview of Australia’s healthcare reimbursement process in Australia, with a focus on the MedTech industry. Presented by George Papadopoulos and Blaise Agresta from Lucid Health Consulting.
Reimbursement is a critical factor in the adoption and success of medical technologies, as Australia operates a centralised system for healthcare funding. This workshop will cover key reimbursement pathways, including:
· The Medicare Benefits Schedule (MBS) for medical services
· The Pharmaceutical Benefits Scheme (PBS) for medicines
· The Prescribed List of Medical Devices and Human Tissue Products (PL), for medical devices and human tissue products for which private health insurers must pay benefits
Participants will gain insights into the key decision-making bodies that govern reimbursement approvals, including the Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC), and Medical Devices and Human Tissue Advisory Committee (MDHTAC).
The workshop will outline the importance of HTA, focusing on value-for-money, comparative evidence, economic evaluations and financial forecasting in reimbursement applications. Additionally, the session will highlight the importance of early planning, strong clinical evidence, and strategic positioning for MedTech organisations aiming to secure reimbursement in the Australian market.
